Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
Proactive Investors : CFO ‘pleased’ with reformulation of degenerative diseases treatment
To view the full article click here…
CFO comments on publication of positive pre-clinical data fron retinitis pigmentosa programme
First Retinal Patient Receives Stem-Cell Therapy in ReNeuron’s Clinical Trial
For the article published by the Foundation for Fighting Blindness Click here..
Interview with Dr. Michael Young, pre-clinical investigator with ReNeuron’s hRPC retinal technology
Interview with Dr. Eric Pierce, Principal Investigator on ReNeuron’s Phase I/II clinical trial for Retinitis Pigmentosa
Pro-Active Investors : ReNeuron making good progress in clinical trials, says CFO
CFO gives interview at Proactive Investors after ReNeuron announces first patient treated in US Phase I/II clinical trial in retinitis pigmentosa
It is hoped that ReNeuron’s treatment will “at the very least” arrest the deterioration in eyesight caused by the disease and in the best case restore sight.
Multimedia Interview with Michael Hunt, ReNeuron Chief Executive Officer – 30th August 2013